Audio Journal of Oncology – June 7th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
Robert Ozols Lawrence Wickerham Patricia Ganz Jorma Paavonen Noah Kauff Robert Ozols of the Fox Chase Cancer Center in Philadelphia joins Derek Thorne to talk about the top presentations on cancer pre
Robert Ozols
Lawrence Wickerham
Patricia Ganz
Jorma Paavonen
Noah Kauff
Robert Ozolsof the Fox Chase Cancer Center in Philadelphia joins Derek Thorne to talk about the top presentations on cancer prevention.
– Raloxifene is as good as tamoxifen at preventing breast cancer in high-risk women.Lawrence Wickerhamof the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh presented the clinical data from the STAR trial, whilePatricia Ganzof UCLA had information on quality of life (Abstracts 5 and 561)
– The human papillomavirus vaccine (HPV) doesn’t just protect against cervical cancer – it may protect against vaginal and vulvar cancers as well. That’s according to findings from the FUTURE II study, presented byJorma Paavonenof the University of Helsinki (Abstract 5011)
–Noah Kauff, of the Memorial Sloan-Kettering Cancer Center in New York, has data confirming that women with mutations in the genes for BRCA1 and 2 can reduce their risk of breast and ovarian cancer if they have their ovaries and fallopian tubes removed (Abstract 1003)
Related Episodes
Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer
Matteo Lambertini MD PhD discusses new findings from the ALTTO trial at the 2025 San Antonio Breast Cancer Symposium. The long-term analysis reveals that adjuvant aromatase inhibitors lead to superior outcomes, including improved disease-free survival and time to distant recurrence, compared to tamoxifen or other SERMs.
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.
Audio Journal of Fertility
Johan Smitz In Manchester, Peter Goodwin hears from MASTERCLASS chair Masoud Afnan, guest experts Johan Smitz and Richard Fleming and participant Gedis Grudzinskas about the evidence base underscoring